MP62-02 30- AND 90-DAY OUTCOMES OF AQUABLATION VS. OTHER SURGICAL TREATMENTS FOR BENIGN PROSTATIC HYPERPLASIA

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV (MP62)1 May 2024MP62-02 30- AND 90-DAY OUTCOMES OF AQUABLATION VS. OTHER SURGICAL TREATMENTS FOR BENIGN PROSTATIC HYPERPLASIA Isabella S. Florissi, Taylor Kohn, Dianelis G. Pupo, Liam Nugent, Mark N. Alshak, Pranjal Agrawal, and Naren Nimmagadda Isabella S. FlorissiIsabella S. Florissi , Taylor KohnTaylor Kohn , Dianelis G. PupoDianelis G. Pupo , Liam NugentLiam Nugent , Mark N. AlshakMark N. Alshak , Pranjal AgrawalPranjal Agrawal , and Naren NimmagaddaNaren Nimmagadda View All Author Informationhttps://doi.org/10.1097/01.JU.0001008904.63948.3b.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Mid- and long-term outcomes of Aquablation as treatment for benign prostatic hyperplasia (BPH) have been well characterized. However, short-term outcomes have not. The aim of this analysis was to compare rates of 30- and 90-day complications following Aquablation to those after transurethral resection of prostate (TURP), UroLift, Holmium Laser Enucleation of the Prostate (HoLEP), and robot-assisted simple prostatectomy (RSP). METHODS: Using the TrinetX Research database, a collaborative claims and electronic medical record research network of 79 healthcare organizations including more than 113 million individual patients, we conducted a propensity-matched retrospective cohort study of all adult male patients who underwent Aquablation (CPT 0421T), Urolift (CPT 52441), HoLEP (CPT 52649), or RSP (CPT 55821) from 2009-October 2023. We performed a propensity score matching for age at time of surgery, hypertension, obesity, and PSA range to determine the relative risk of developing the following outcomes at 30- and 90-days postoperatively: visit to the emergency department (ED), hospital readmission, catheter re-insertion, and urinary tract infection (UTI). RESULTS: Prior to matching, data were available for 1,171 Aquablation, 27,989 TURP, 3,999 Urolift, 4,879 HoLEP, and 1,047 RSP patients. After matching Aquablation to each other procedure, the cohorts ranged in size from 630 to 1,171. Patients who underwent Aquablation were less likely than TURP and RSP patients to visit the emergency department at 30- and 90-days. However, they were more likely to be readmitted to the hospital than those who underwent HoLEP and UroLift, but less likely than RSP patients at 30- and 90- days postoperatively. Patients who underwent Aquablation were less likely to have a UTI at 30- and 90- days postoperatively than patients who underwent TURP, HoLEP, and RSP. Patients who underwent Aquablation were more likely to experience catheter re-insertion at 30- and 90- days postoperatively than patients who underwent HoLEP and RSP. CONCLUSIONS: Our findings suggest that patients undergoing Aquablation experience similar rates of short- and intermediate-term complications to TURP but higher rates of hospital re-admission and catheter re-insertion than other surgical BPH cohorts. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1020 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Isabella S. Florissi More articles by this author Taylor Kohn More articles by this author Dianelis G. Pupo More articles by this author Liam Nugent More articles by this author Mark N. Alshak More articles by this author Pranjal Agrawal More articles by this author Naren Nimmagadda More articles by this author Expand All Advertisement PDF downloadLoading ...